Reviva Pharmaceuticals Holdings, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
OQB
Parag Saxena has reduced his beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. to 2.8% as of March 20, 2026, triggering an Amendment No. 13 filing.
OQB
SCHEDULE 13D/A: Vedanta Partners Reduces Reviva Pharma Stake Below 5%
Vedanta Partners, LLC has reduced its beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. to below 5%, while Parag Saxena maintains a 5.2% stake.
OQB
Dr. Laxminarayan Bhat's beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. has decreased to 3.8%, falling below the 5% reporting threshold.
OQB
Vedanta Partners and Parag Saxena filed an Amendment No. 11 to their Schedule 13D, updating their beneficial ownership in Reviva Pharmaceuticals Holdings, Inc.
OQB
An amended Schedule 13D filing reveals that Vedanta Associates, L.P. has reduced its beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. to below the 5% threshold, while other affiliated entities and individuals maintain significant stakes.
OQB
SCHEDULE: Laxminarayan Bhat Amends Reviva Pharmaceuticals Holdings Stake, Reports 5.2% Beneficial Ownership
Laxminarayan Bhat has filed Amendment No. 5 to his Schedule 13D, disclosing a beneficial ownership of 5.2% of Reviva Pharmaceuticals Holdings, Inc.'s common stock, totaling 3,612,384 shares.
OQB
SCHEDULE 13D/A: Vedanta Entities Update Stake in Reviva Pharmaceuticals, Parag Saxena Maintains 12.4% Beneficial Ownership
Vedanta Management entities, including Parag Saxena, have filed an Amendment No. 9 to their Schedule 13D, detailing updated beneficial ownership percentages in Reviva Pharmaceuticals Holdings, Inc., with some entities falling below the 5% threshold.